FOLFOX方案与ECF方案治疗晚期胃癌临床对比研究

目的观察比较FOLFOX方案与ECF方案治疗晚期胃癌的疗效、毒副反应。方法 84例晚期胃癌随机分为FOLFOX组与ECF组,近期疗效及毒副反应按WHO标准进行评价。结果 FOLFOX组总有效率、初治有效率分别为47.6%、57.1%、与ECF方案疗效相近;FOLFOX组KPS评分改善率是64.3%,较ECF组明显提高,差异有统计学意义(P<0.05)。毒副反应观察Ⅲ～Ⅳ度白细胞减少率、恶心呕吐发生率、脱发发生率FOLFOX组均明显低于ECF组,差异有统计学意义(P<0.01);FOLFOX组神经毒性多为Ⅰ、Ⅱ度,而且对肝肾功能影响不大。结论 FOLFOX方案治疗晚期胃癌安全、有效,值得临床推广研究。

Objective To compare the effect and toxicity between FOLFOX regimen and ECF regimen in patients with advanced gastric cancer. Methods Eighty-four patients with advanced gastric cancer were randomly divided into FOLFOX group and ECF group. Objective tumor response and toxicity reactions were assessed by WHO criteria. Results The overall response rate, the first treatment response rate were 47.6%,57.1% in the group FOLFOX, with the ECF program similar efficacy; Karnofsky improvement rate was 64.3% in the group FOLFOX, significantly higher than ECF group, and the difference was statistically significant （P〈0,05） .Toxicity on HI - IV neutropenia, nausea, vomiting, hair loss were observed, the incidence of FOLFOX group were significantly lower than the ECF group. There was significant difference between the two groups（P〈0.01）. Neurotoxicity in the group FOLFOX was mostly grade Ⅰ and Ⅱ, little effect on the liver and kidney function was observed in the group FOLFOX. Conclusions FOLFOX regimen may be safe and effective for advanced gastric cancer, it is worthy of clinical study.